Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.

@article{Wrishko2009SafetyEA,
  title={Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil.},
  author={Rebecca E. Wrishko and Sebastian Sorsaburu and David Wong and Andrew B Strawbridge and James F. McGill},
  journal={The journal of sexual medicine},
  year={2009},
  volume={6 7},
  pages={2039-48}
}
INTRODUCTION Several phosphodiesterase type 5 (PDE5) inhibitors are commercially available for the treatment of erectile dysfunction (ED). Development of the first once-daily alternative dosing regimen with a PDE5 inhibitor was motivated by the behavioral complexities associated with sexual intimacy. AIM To provide an alternative dosing option for certain men who may benefit from the removal of the temporal linkage between administration of an ED therapy and sexual intimacy or for men and… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

Drug design, development and therapy • 2010
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…